Tolerability and efficacy of pegylated consensus interferon-α in the treatment of chronic hepatitis C

作者：Ding, Yan-Hua; Liu, Bin; Zhang, Xin; Sun, Li; Zhang, Hong; Luo, Hua; Sun, Yan-Fu; Liu, Cheng-Jiao; Zhang, Qi; Cao, Yu-Chen; Chen, Hong^*; Niu, Jun-Qi^*

来源：Experimental and Therapeutic Medicine, 2017, 13(1): 9-16.

DOI：10.3892/etm.2016.3914

• recombinant interferon
• tolerance
• adverse event
• efficacy

This study aimed to explore and evaluate the tolerability and antiviral activity of pegylated recombinant human consensus interferon-alpha (PEG-CIFN) in adults with hepatitis C virus (HCV) infection. A total of 48 adult subjects chronically infected with HCV were divided into five groups, which were treated separately with PEG-CIFN 1.0 mu g/kg (n=10), 1.5 mu g/kg (n=10), 2.0 mu g/kg (n=9) or 3.0 mu g/kg (n=10), or pegylated IFN alpha-2a (Pegasys) 180 mu g (n=9) as controls. Symptoms were observed and laboratory results collected to monitor adverse reactions, adjust drug dosage and evaluate tolerability. The thrombocytopenic effects in all PEG-CIFN dose groups were less than that of pegylated IFN alpha-2a (at week 14, P<0.05). The rapid virologic response of the PEG-CIFN 1.5, 2.0 and 3.0 mu/g/kg groups and the pegylated IFN alpha-2a group were significantly higher than that of the PEG-CIFN 1.0 mu g/kg group (P<0.05). Patients who had HCV genotype 1b infections had relatively high responses. The early virologic response of the PEG-CIFN 1.0, 1.5 and 2.0 mu g/kg groups and the pegylated IFN alpha-2a group were 30, 90, 88.8 and 88.8% respectively. PEG-CIFN is well tolerated, and was found to have dose-dependent effectiveness in subjects with chronic hepatitis C. Virological response rates between PEG-CIFN 1.5 or 2.0 mu g/kg, and pegylated IFN alpha-2a were similar, and not significantly different. It is concluded that 1.5 mu g/kg PEG-CIFN may be the clinically recommended dose. PEG-CIFN is superior to pegylated IFN alpha-2a in maintaining platelet levels.

• 出版日期2017-1
• 单位吉林大学